LDL Reduction Calculator

Statin Intensity & Combination Therapy — Expected LDL Lowering

Current / Baseline LDL-C

mg/dL

Statin Intensity

EzetimibeAdditional ~22% reduction of remaining LDL

Bempedoic AcidAdditional ~17% reduction of remaining LDL

PCSK9 Inhibitor (e.g., Evolocumab, Alirocumab)Additional ~55% reduction of remaining LDL

InclisiranAdditional ~50% reduction of remaining LDL

LDL Target

Baseline LDL — mg/dL

Expected LDL on Therapy — mg/dL

Total LDL Reduction —

LDL Target —

At Target? —

Enter baseline LDL and select therapy to see results.

High Intensity (~50% LDL reduction): Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg
Moderate Intensity (~30-49% LDL reduction): Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg
Low Intensity (~30% LDL reduction): Simvastatin 10 mg, Pravastatin 10-20 mg, Lovastatin 20 mg, Fluvastatin 20-40 mg

Reductions are applied multiplicatively — each add-on therapy reduces the remaining LDL after prior therapies, not the original baseline.
PCSK9 inhibitors and Inclisiran both target the PCSK9 pathway and should not be combined. If both are selected, only the PCSK9 inhibitor reduction (55%) is applied.
Individual patient responses may vary. These are average expected reductions based on clinical trial data.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. DOI: 10.1161/CIR.0000000000000625
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. DOI: 10.1093/eurheartj/ehz455